Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria.
Mefloquine has an established place in the treatment of chloroquine-resistant falciparum malaria. To investigate mefloquine pharmacokinetics in pregnancy, 9 untreated pregnant women aged 16-33 years and 8 non-pregnant females aged 16-38 years received an average of 15 (range 13-19) mg mefloquine/kg...
| Huvudupphovsmän: | , , , , , |
|---|---|
| Materialtyp: | Journal article |
| Språk: | English |
| Publicerad: |
1994
|
| _version_ | 1826297333686468608 |
|---|---|
| author | Na Bangchang, K Davis, T Looareesuwan, S White, N Bunnag, D Karbwang, J |
| author_facet | Na Bangchang, K Davis, T Looareesuwan, S White, N Bunnag, D Karbwang, J |
| author_sort | Na Bangchang, K |
| collection | OXFORD |
| description | Mefloquine has an established place in the treatment of chloroquine-resistant falciparum malaria. To investigate mefloquine pharmacokinetics in pregnancy, 9 untreated pregnant women aged 16-33 years and 8 non-pregnant females aged 16-38 years received an average of 15 (range 13-19) mg mefloquine/kg body-weight as single-dose treatment for uncomplicated falciparum malaria. Regular blood samples were taken during the subsequent 48 h and then intermittently for 3-26 d after treatment. Whole blood mefloquine concentrations were analysed by high-performance liquid chromatography and a one-compartment open pharmacokinetic model was fitted to the data. Peak mefloquine concentrations were significantly lower in the pregnant patients (median [range]; 1257 [650-1584] vs. 1617 [1051-3111] ng/mL) and the total apparent volume of distribution (Vd/f) was larger (10.8 [8.3-26.1] vs. 10.0 [4.8-13.9] L/kg; P < 0.05 in each case), consistent with an expanded circulating blood volume and increased tissue binding in pregnancy. There was no significant difference between the 2 groups in half-times of absorption or elimination (P > 0.1), and systemic clearance rates were also similar. These results suggest that pregnant patients need larger doses of mefloquine than non-pregnant women to achieve comparable blood levels, an important consideration in areas where multi-drug resistant falciparum malaria is emerging. |
| first_indexed | 2024-03-07T04:30:00Z |
| format | Journal article |
| id | oxford-uuid:cdf936b5-4428-4c1f-aa31-c9c6a2fcaff5 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:30:00Z |
| publishDate | 1994 |
| record_format | dspace |
| spelling | oxford-uuid:cdf936b5-4428-4c1f-aa31-c9c6a2fcaff52022-03-27T07:32:32ZMefloquine pharmacokinetics in pregnant women with acute falciparum malaria.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cdf936b5-4428-4c1f-aa31-c9c6a2fcaff5EnglishSymplectic Elements at Oxford1994Na Bangchang, KDavis, TLooareesuwan, SWhite, NBunnag, DKarbwang, JMefloquine has an established place in the treatment of chloroquine-resistant falciparum malaria. To investigate mefloquine pharmacokinetics in pregnancy, 9 untreated pregnant women aged 16-33 years and 8 non-pregnant females aged 16-38 years received an average of 15 (range 13-19) mg mefloquine/kg body-weight as single-dose treatment for uncomplicated falciparum malaria. Regular blood samples were taken during the subsequent 48 h and then intermittently for 3-26 d after treatment. Whole blood mefloquine concentrations were analysed by high-performance liquid chromatography and a one-compartment open pharmacokinetic model was fitted to the data. Peak mefloquine concentrations were significantly lower in the pregnant patients (median [range]; 1257 [650-1584] vs. 1617 [1051-3111] ng/mL) and the total apparent volume of distribution (Vd/f) was larger (10.8 [8.3-26.1] vs. 10.0 [4.8-13.9] L/kg; P < 0.05 in each case), consistent with an expanded circulating blood volume and increased tissue binding in pregnancy. There was no significant difference between the 2 groups in half-times of absorption or elimination (P > 0.1), and systemic clearance rates were also similar. These results suggest that pregnant patients need larger doses of mefloquine than non-pregnant women to achieve comparable blood levels, an important consideration in areas where multi-drug resistant falciparum malaria is emerging. |
| spellingShingle | Na Bangchang, K Davis, T Looareesuwan, S White, N Bunnag, D Karbwang, J Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. |
| title | Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. |
| title_full | Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. |
| title_fullStr | Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. |
| title_full_unstemmed | Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. |
| title_short | Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. |
| title_sort | mefloquine pharmacokinetics in pregnant women with acute falciparum malaria |
| work_keys_str_mv | AT nabangchangk mefloquinepharmacokineticsinpregnantwomenwithacutefalciparummalaria AT davist mefloquinepharmacokineticsinpregnantwomenwithacutefalciparummalaria AT looareesuwans mefloquinepharmacokineticsinpregnantwomenwithacutefalciparummalaria AT whiten mefloquinepharmacokineticsinpregnantwomenwithacutefalciparummalaria AT bunnagd mefloquinepharmacokineticsinpregnantwomenwithacutefalciparummalaria AT karbwangj mefloquinepharmacokineticsinpregnantwomenwithacutefalciparummalaria |